---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-147339"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T18:13:30.380569+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Vor Bio licenses telitacicept from RemeGen for $125M upfront, raises $175M PIPE, appoints new CEO

## Summary
- License deal: Vor Bio gets ex-China rights to telitacicept (global Phase 3 for gMG) for $125M upfront ($45M cash + $80M warrants); up to $4B+ milestones plus royalties.
- Private Placement: $175M gross from pre-funded warrants to buy 700M shares at $0.25/warrant; closing expected June 27, 2025.
- CEO change: Robert Ang resigned; Jean-Paul Kress (ex-MorphoSys CEO) appointed CEO and Chairman. Dr. Ang stays as advisor through October.
- Cambridge lease terminated: $8.5M termination fee paid; $2.4M letter of credit to be returned. Lease was set to expire in 2030.
- Stockholders representing ~63% voting power signed support agreements to approve share issuance and charter amendment.

## SEC filing metadata
- accession: 0001193125-25-147339
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 1.02, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312525147339/0001193125-25-147339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312525147339/d27026d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-147339
- JSON: https://secwatch.observer/filing/0001193125-25-147339.json
- Plain text: https://secwatch.observer/filing/0001193125-25-147339.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.